Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Tapering of TNF inhibitors in axial spondyloarthritis in routine care-2-year clinical and MRI outcomes and predictors of successful tapering

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Increased risk of thoracic aortic complications among patients with giant cell arteritis: a nationwide, population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Musculoskeletal pain in psoriasis - relation to inflammation and additional value of ultrasound in psoriatic arthritis classification

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. CXCL13 predicts long term radiographic status in early rheumatoid arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Improving the design of RCTs in non-radiographic axial spondyloarthritis

    Research output: Contribution to journalReviewResearchpeer-review

  2. Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Musculoskeletal pain in psoriasis - relation to inflammation and additional value of ultrasound in psoriatic arthritis classification

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

OBJECTIVES: In a 2-year follow-up study of patients with axial spondyloarthritis (axSpA) in clinical remission who tapered TNF inhibitor (TNFi) treatment according to a clinical guideline, we aimed to investigate the proportion who successfully tapered/discontinued therapy and baseline predictors thereof. The proportion regaining clinical remission after flare and the progression on MRI/radiography were also assessed.

METHODS: One-hundred-and-nine patients (78 [72%]/31 [28%] receiving standard and reduced dose, respectively) in clinical remission (BASDAI < 40, physician global score < 40) and no signs of disease activity the previous year tapered TNFi as follows: to two-thirds of standard dose at baseline, half at week 16, one-third at week 32 and discontinuation at week 48. Patients experiencing clinical, BASDAI or MRI flare (predefined criteria) stopped tapering and escalated to previous dose. Prediction analyses were performed by multivariable regression.

RESULTS: One hundred and six patients (97%) completed 2 years' follow-up; 55 patients (52%) had successfully tapered: 23 (22%) receiving two-thirds, 15 (14%) half, 16 (15%) one-third dose and 1 (1%) discontinued. In patients at standard dose at baseline (n = 78), lower physician global score was the only independent predictor of successful tapering (odds ratio [OR] = 0.79 [95% CI: 0.64, 0.93]; P = 0.003). In the entire patient group lower physician global score (OR = 0.86 [0.75, 0.98]; P = 0.017), lower Spondyloarthritis Research Consortium of Canada (SPARCC) Sacroiliac Joint Erosion score (OR = 0.78 [0.57, 0.98]; P = 0.029) and current smoker (OR = 3.28 [1.15, 10.57]; P = 0.026) were independent predictors of successful tapering. At 2 years, 97% of patients were in clinical remission. Minimal changes in imaging findings were observed.

CONCLUSION: After 2 years following a clinical guideline, 52% of patients with axSpA in clinical remission had successfully tapered TNFi, only 1% discontinued. Baseline physician global score was an independent predictor of successful tapering.

Original languageEnglish
JournalRheumatology (Oxford, England)
Volume61
Issue number6
Pages (from-to)2398-2412
Number of pages15
ISSN1462-0324
DOIs
Publication statusPublished - 30 May 2022

Bibliographical note

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

    Research areas

  • Antirheumatic Agents/therapeutic use, Axial Spondyloarthritis, Follow-Up Studies, Humans, Magnetic Resonance Imaging/methods, Spondylarthritis/diagnostic imaging, Treatment Outcome, Tumor Necrosis Factor Inhibitors/therapeutic use, axSpA, MRI, successful tapering, prediction, TNF inhibitors

ID: 70405676